Expression of ERα, its ERαΔ3 Splice Variant and γ-SYNUCLEIN in Ovarian Cancer: A Pilot Study

References (40)

1. 1 Loss of Epigenetic Control of Synuclein-γ Gene as a Molecular Indicator of Metastasis in a Wide Range of Human Cancers [DOI]
2. 2 Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer.
3. 3 Ovarian cancer: pathology, biology, and disease models [DOI]
4. 4 Synuclein-γ Is Closely Involved in Perineural Invasion and Distant Metastasis in Mouse Models and Is a Novel Prognostic Factor in Pancreatic Cancer [DOI]
5. 5 Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
6. 6 Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary [DOI]
7. 7 Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas [DOI]
8. 8 γ-Synuclein Promotes Cancer Cell Survival and Inhibits Stress- and Chemotherapy Drug-induced Apoptosis by Modulating MAPK Pathways [DOI]
9. 9 Oestrogen receptor splice variants in the pathogenesis of disease [DOI]
10. 10 Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, γ‐synuclein, and catechol‐o‐methyltransferase) identified by proteomic analysis [DOI]
11. 11 γ‐Synuclein and the progression of cancer [DOI]
12. 12 Loss of estrogen receptor β isoform expression and its correlation with aberrant DNA methylation of the 5′‐untranslated region in human epithelial ovarian carcinoma [DOI]
13. 13 Antiangiogenic drugs in ovarian cancer [DOI]
14. 14 γ Synuclein, a Novel Heat-Shock Protein-Associated Chaperone, Stimulates Ligand-Dependent Estrogen Receptor α Signaling and Mammary Tumorigenesis [DOI]
15. 15 Stage-specific expression of breast cancer-specific gene gamma-synuclein.
16. 16 Angiogenesis and ovarian cancer [DOI]
17. 17 Expression of concern: Overexpression of synuclein‐γ in pancreatic adenocarcinoma [DOI]
18. 18 Stimulation of estrogen receptor signaling by gamma synuclein.
19. 19 Demethylation of the Synuclein γ Gene CpG Island in Primary Gastric Cancers and Gastric Cancer Cell Lines [DOI]
20. 20 Synuclein-γ Targeting Peptide Inhibitor that Enhances Sensitivity of Breast Cancer Cells to Antimicrotubule Drugs [DOI]
21. 21 Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis [DOI]
22. 22 Up‐regulation of gamma‐synuclein contributes to cancer cell survival under endoplasmic reticulum stress [DOI]
23. 23 The Expression of Vascular Endothelial Growth Factor and Transforming Growth Factor-β Associates With Angiogenesis in Epithelial Ovarian Cancer [DOI]
24. 24 Expression of alternatively spliced estrogen receptor alpha mRNAs is increased in breast cancer tissues [DOI]
25. 25 Alterations in SPARC and VEGF Immunoreactivity in Epithelial Ovarian Cancer [DOI]
26. 26 Loss of an Estrogen Receptor Isoform (ERαΔ3) in Breast Cancer and the Consequences of Its Reexpression: Interference with Estrogen-Stimulated Properties of Malignant Transformation [DOI]
27. 27 The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer.
28. 28 Elevated expression of CYP1A1 and -SYNUCLEIN in human ectopic (ovarian) endometriosis compared with eutopic endometrium [DOI]
29. 29 Involvement of RHO GTPases and ERK in synuclein-γ enhanced cancer cell motility [DOI]
30. 30 Chaperoning of estrogen receptor and induction of mammary gland proliferation by neuronal protein synuclein gamma [DOI]
31. 31 Activation of vascular endothelial growth factor (VEGF) by the ER-α variant, ERΔ3 [DOI]
32. 32 Survival from cancer of the ovary in England and Wales up to 2001 [DOI]
33. 33 Applications of novel monoclonal antibodies specific for synuclein-γ in evaluating its levels in sera and cancer tissues from colorectal cancer patients [DOI]
34. 34 Targeting synuclein-γ to counteract drug resistance in cancer [DOI]
35. 35 Expression of γ-synuclein in colorectal cancer tissues and its role on colorectal cancer cell line HCT116 [DOI]
36. 36 Functionally active estrogen receptor isoform profiles in the breast tumors of African American women are different from the profiles in breast tumors of Caucasian women [DOI]
37. 37 Current status of anti-angiogenic agents in the treatment of ovarian carcinoma [DOI]
38. 38 Aberrant expression and demethylation of γ‐synuclein in colorectal cancer, correlated with progression of the disease [DOI]
39. 39 Expression of γ-synuclein in colorectal cancer tissues and its role on colorectal cancer cell line HCT116
40. 40 The Synuclein Family [DOI]

Cited by 14

Showing 11 of 14 known citations — external sources report more than can currently be individually listed.

Related research

• Diagnostic Role of Aberrant DNA Promoter Methylation in Ovarian Cancer — shares topic coverage
• Role of Human Beta Defensin-2 and Oxidative Stress Parameters in Ovarian Cancer Patients — shares topic coverage
• A Review on the Evolutionary Trajectories of mRNA BRCA1/2 Genes in Primates and the Implications of Cancer Susceptibility Variants within Immediate Human Populations — shares topic coverage
• MicroRNAs Indirectly Regulate Other MicroRNAs in Ovarian Cancer Cells — shares topic coverage
• Impact of Hormonal Status on Outcome of Aromatase Inhibitor Maintenance Post-adjuvant Chemotherapy in High Grade Serous Ovarian Cancer (HGSOC): A Phase II Study — shares topic coverage